In 2017, the entry that became Diabetes Mechanism Analysis \u2014 Proof of Function #1<\/a> was written down as Invent Deposition #3361<\/strong>:<\/p>\n “Immune systemic insulin. insulin medicine to magistrate through the auto immune system immune systemic insulin. insulin medicine to magistrate through the auto immune system insulin main article: insulin therapy type 1 diabetes is typically treated with a combinations of regular and nph insulin, or synthetic insulin analogs. when insulin is used in type 2 diabetes, a long-acting formulation is usually added initially, while continuing oral medications.[29] doses of insulin are then increased to effect.[29] http:\/\/en.wikipedia.org\/wiki\/diabetic.”— © 2017 Christopher Gabriel Brown<\/span><\/p>\n<\/blockquote>\n The 2017 entry was a single-line directive: write down the mechanism, not the brand. Between then and the Proof of Function shipping on this storefront, the work hardened into a 300-row mechanism-analysis database: each row a candidate disease driver, each column a molecular pathway under closed-loop, design-target conditions. Patent-pending. The Proof of Function exposes the database structure, the scoring rubric, and the redaction layer that lets a partner work the IP without exposing the AES-encrypted source archive.<\/p>\n\n
What changed between 2017 and the product on the shelf<\/h2>\n
Where it sits in the four-step framework<\/h2>\n
\n